Table 3.
Clinical and serological features of patients treated with sarilumab.
| Sarilumab (n=25) | Standard of care(n=68) | p value | PaO2/FiO2 ratio ≥ 100 mmHg | PaO2/FiO2 ratio < 100 mmHg | |||||
|---|---|---|---|---|---|---|---|---|---|
| Sarilumab (n=8) | Standard of care(n=33) | p value | Sarilumab (n=17) | Standard of care(n=35) | p value | ||||
| Age (years) | 56 (50-62) | 61 (55-67) | 0.07 | 56 (52-62) | 60 (52-64) | 0.74 | 56 (48-60) | 61 (57-64) | 0.07 |
| Male sex, n (%) | 16 (64%) | 37 (54%) | 0.48 | 6 (75%) | 23 (70%) | 0.99 | 10 (59%) | 14 (40%) | 0.24 |
| Comorbidities | |||||||||
| HBP | 5 (20%) | 27 (39%) | 0.09 | 1 (12%) | 10 (30%) | 0.41 | 4 (23%) | 17 (49%) | 0.13 |
| CAD | 2 (8%) | 8 (12%) | 0.72 | 1 (12%) | 2 (6%) | 0.49 | 1 (6%) | 6 (17%) | 0.4 |
| Type 2 diabetes | 1 (4%) | 14 (21%) | 0.07 | 0 (0%) | 6 (18%) | 0.32 | 1 (6%) | 8 (23%) | 0.24 |
| COPD | 0 (0%) | 5 (7%) | 0.32 | 0 (0%) | 1 (3%) | 0.99 | 0 (0%) | 4 (11%) | 0.29 |
| Cancer | 1 (4%) | 6 (9%) | 0.67 | 0 (0%) | 6 (18%) | 0.32 | 1 (6%) | 0 (0%) | 0.33 |
| CRF | 0 (0%) | 2 (3%) | 0.9 | 0 (0%) | 0 (0%) | 0.99 | 0 (0%) | 2 (6%) | 0.99 |
| PaO2/FiO2 ratio (mmHg) | 87 (74-123) | 96 (71-146) | 0.38 | 138 (122-184) | 148 (116-187) | 0.98 | 81 (69-87) | 72 (61-89) | 0.48 |
| Laboratory values | |||||||||
| LAD (125-220 IU/L) |
477 (420-591) | 522 (403-632) | 0.47 | 444 (327-489) | 459 (386-541) | 0.46 | 488 (438-602) | 585 (447-726) | 0.21 |
| CRP (< 6 mg/L) | 132 (102-219) | 176 (122-230) | 0.23 | 143 (112-179) | 153 (118-192) | 0.58 | 122 (100-241) | 202 (132-238) | 0.24 |
| Ferritin (30-400 ng/mL) |
1890 (1028-3050) | 2486 (1237-3500) | 0.36 | 1098 (876-1550) | 1876 (1217-3450) | 0.07 | 2611 (1410-3883) | 1482 (1077-3720) | 0.7 |
| IL6 (<7 pg/mL) | 60 (38-129) | 51 (28-143) | 0.41 | 88 (43-164) | 42 (26-170) | 0.27 | 60 (36-127) | 99 (66-270) | 0.1 |
Results are reported as median (interquartile range) unless specified; statistically significant p value < 0.05. HBP, high blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; LAD, lactate dehydrogenase; CRP, C-reactive protein; IL-6, interleukin-6.